ArticleTranslational cancer research2025
Enhanced prognostic prediction of cancer-specific mortality in elderly bladder cancer patients post-radical cystectomy: an XGBoost model study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning to identify heart failure with preserved ejection fraction in type 2 diabetes mellitus patients.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor stage, surgery and age are positively correlated with cancer-specific mortality (CSM) in patients diagnosed with bladder cancer (BCa). In light of the successful application of machine learning to process big data in many fields outside of medicine, we aimed to establish and validate whether machine learning models could improve our ability to predict the development of CSM in elderly BCa patients after radical cystectomy (RC). Methods: Data on eligible patients diagnosed with BCa were obtained from the Surveillance, Epidemiology, and End Results database (2000-2021) and divided into training and validation cohorts in a ratio of 7:3. First, risk factors for the development of CSM in patients were identified by Cox regression analysis. Then, iterative testing and tuning through automated hyperparameter optimization and ten-fold cross-validation were performed to generate stable extreme gradient boosting (XGBoost) models with optimal performance. Receiver operating characteristic (ROC) curve, area under the curve (AUC), calibration curve and confusion matrix were used to evaluate the performance of XGBoost model. Results: There were 11,763 patients included, of which 5,788 died from BCa. By the comparison of different machine learning models, the final XGBoost model we constructed showed high accuracy and precision in predicting the development of CSM in BCa patients (6-month CSM: AUC =0.799, 12-month CSM: AUC =0.756, 36-month CSM: AUC =0.746, and 60-month CSM: AUC =0.745). The results of accuracy, precision, recall and F1 score confirmed the superior performance of the XGBoost model. The important scores for clinical characteristics and the Shapley Additive Explanations plots highlighted the importance of key factors: chemotherapy, tumor stage, marital status, and tumor size were the top four factors in all models. Conclusions: Our study validated and confirmed the feasibility and high performance of the XGBoost model in predicting CSM in elderly BCa patients after RC. The potential of machine learning contributes to accurately predict the prognosis of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.